Modulator Effects of Meloxicam against Doxorubicin-Induced Nephrotoxicity in Mice

Journal of Biochemical and Molecular Toxicology

Volumn 28, Issue 8, 2014, Pages 337-346

  Hassan, Memy H ^a,b   Ghobara, Mohamed ^a,c   Abd Allah, Gamil M ^b  

^a TAIBAH UNIVERSITY   (Saudi Arabia)

^b Al Azhar University   (Egypt)

^c TANTA UNIVERSITY   (Egypt)

Author keywords

Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Doxorubicin; Meloxicam

Indexed keywords

CASPASE 3; CATALASE; CREATININE; DOXORUBICIN; GLUTATHIONE; GLUTATHIONE PEROXIDASE; INTERLEUKIN 6; MELOXICAM; PROSTAGLANDIN E2; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR ALPHA; URIC ACID; THIAZINE DERIVATIVE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; CREATININE BLOOD LEVEL; ENZYME ACTIVITY; HISTOPATHOLOGY; KIDNEY FUNCTION TEST; KIDNEY MASS; LIPID PEROXIDATION; MALE; MORTALITY; MOUSE; NEPHROTOXICITY; NONHUMAN; UREA NITROGEN BLOOD LEVEL; ANIMAL; BLOOD; CHEMICALLY INDUCED; DRUG EFFECTS; HUMAN; NEOPLASMS; OXIDATIVE STRESS; PATHOLOGY; RENAL INSUFFICIENCY;

ANIMALS; CASPASE 3; DINOPROSTONE; DOXORUBICIN; HUMANS; INTERLEUKIN-6; LIPID PEROXIDATION; MALE; MICE; NEOPLASMS; OXIDATIVE STRESS; RENAL INSUFFICIENCY; THIAZINES; THIAZOLES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84905368399     PISSN: 10956670     EISSN: 10990461     Source Type: Journal    
DOI: 10.1002/jbt.21570     Document Type: Article

References (72)

1. Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E III, editors. Cancer medicine, 6th edition. Hamilton, Ontario, Canada: BC Decker; 2003. pp 569-583.
2. Rayson D, Richel D, Chia S, Jackisch C, van der Vegt S, Suter T. Anthracycline-trastuzumab regimens for HER2/ neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol 2008;19:1530-1539.
3. Gewirtz DA. A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem Pharmacol 1999;57:727-741.
4. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004;56:185-229.
5. Sinha BK, Trush MA, Kennedy KA, Mimnaugh EG. Enzymatic activation and binding of adriamycin to nuclear DNA. Cancer Res 1984;44:2892-2896.
6. Binaschi M, Bigioni M, Cipollone A, Rossi C, Goso C, Maggi CA, Capranico G, Animati F. Anthracyclines: selected new developments. Curr Med Chem Anticancer Agents 2001;1:113-130.
7. Muindi JR, Sinha BK, Gianni L, Myers CE. Hydroxyl radical production and DNA damage induced by anthracycline- iron complex. FEBS Lett 1984;172:226-230.
8. Myers CE, mcguire WP, Liss RH, Ifrim I, Grotzinger K, Young RC. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science 1977;197:165-167.
9. Wu X, Hasinoff BB. The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. Anticancer Drugs 2005;16:93-99.
10. Taskin E, Dursun N. The protection of selenium on adriamycin-induced mitochondrial damage in rat. Biol Trace Elem Res 2012;147(1-3):165-171.
11. Wang Y, Wang YP, Tay Y, Harris DC. Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int 2000;58(4):1797-1804.
12. Van den Branden C, Deman A, Ceyssens B, Pauwels M, Empsen C, Verbeelen D. Vitamin E protects renal antioxidant enzymes and attenuates glomerulosclerosis in adriamycin-treated rats. Nephron 2002;91(1):129-133.
13. Deman A, Ceyssens B, Pauwels M, Zhang J, Houte KV, Verbeelen D, Van den Branden C. Altered antioxidant defence in a mouse adriamycin model of glomerulosclerosis. Nephrol Dial Transplant 2001;16(1):147-150.
14. Della-Torre P. Long-lasting effect of dexrazoxone against anthracycline cardiotoxicity in rats. Toxicol Pathol 1996;24:398-402.
15. Adderley S, Fitzgerald D. Oxidative damage of cardiomyocytes is limited by extracellular regulated kinases 1/2-mediated induction of cyclooxygenase 2. J Biol Chem 1999;27:5038-5046.
16. Wolfesberger B, Hoelzl C, Walter I, Reider GA, Fertl G, Thalhammer JG, Skalicky M, Egerbacher M. In vitro effects of meloxicam with or without doxorubicin on canine osteosarcoma cells. J Vet Pharmacol Ther 2006;29(1):15-23.
17. Mizutani Y, Kamoi K, Ukimura O, Kawauchi A, Miki T. Synergistic cytotoxicity and apoptosis of JTE-522, a selective cyclooxygenase-2 inhibitor, and 5-fluorouracil against bladder cancer. J Urol 2002;168(6):2650-2654.
18. Zimmermann KC, Sarbia M, Weber AA, Borchard F, Gabbert HE, Schror K. Cyclooxygenase-2 expression in human esophageal carcinoma. Cancer Res 1999;59:198-204.
19. Arun B, Goss P. The role of COX-2 inhibition in breast cancer treatment and prevention. Semin Oncol 2004;31:22-29.
20. Puhlmann U, Ziemann C, Ruedell G, Vorwerk H, Schaefer D, Langebrake C, Schuermann P, Creutzig U, Reinhardt D. Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells. J Pharmacol Exp Ther 2005;312(1):346-354.
21. Cao Y, Prescott SM. Many actions of cyclooxygenase-2 in cellular dynamics and in cancer. J Cell Physiol 2002;190:279-286.
22. Han HK, Choi HK. Improved absorption of meloxicam via salt formation with ethanolamines. Eur J Pharm Biopharm 2007;65:99-103.
23. Gates BJ, Nguyen TT, Setter SM, Davies NM. Meloxicam: a reappraisal of pharmacokinetics, efficacy and safety. Expert Opin Pharmacother 2005;6:2117-2140.
24. Kalonia H, Kumar A. Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats. Life Sci 2011;88:784-791.
25. Edfawy M, Hassan MH, Mansour A, Hamed AA, Amin HA. Meloxicam modulates oxidative stress status, inhibits prostaglandin E2, and abrogates apoptosis in carbon tetrachloride-induced rat hepatic injury. Int J Toxicol 2012;31(3):276-286.
26. Azab SS, Salama SA, Hassan MH, Khalifa AE, El-Demerdash E, Fouad H, Al-Hendy A, Abdel-Naim AB. 2-Methoxyestradiol reverses doxorubicin resistance in human breast tumor xenograft. Cancer Chemother Pharmacol 2008;62(5):893-902.
27. Eralp Y, Wang X, Wang JP, Maughan MF, Polo JM, Lachman LB. Doxorubicin and paclitaxel enhance the antitumor efficacy of vaccines directed against HER 2/neu in a murine mammary carcinoma model. Breast Cancer Res 2004;6(4):R275-R283.
28. Tubbs JT, Kissling GE, Travlos GS, Goulding DR, Clark JA, King-Herbert AP, Blankenship-Paris TL. Effects of buprenorphine, meloxicam, and flunixin meglumine as postoperative analgesia in mice. J Am Assoc Lab Anim Sci 2011;50(2):185-191.
29. University of Kentucky. 2009. Division of laboratory animal resources, (cited September 8, 2009). Available at http://www.rgs.uky.edu/dlar/animal_health.html (accessed February 10, 2014).
30. University of Rochester Medical Center. 2006. University committee of animal resources, (cited September 8, 2009). Available at: http://www.urmc.rochester.edu/UCAR/manual/table1.htm (accessed February 10, 2014).
31. Bancroft J, Stevens A. Enzyme histochemistry: theory and practice of histological techniques. New York: Churchill Livingstone; 1996.
32. Abrams JS. Immunoenzymatic assay of cytokines using NIP-labeled antibodies. In: Coligan J, Kruisbeck A, Margulies D, Shevach E, Strober W, editors. Current protocols in immunology. New York: Wiley; 1995. pp 620-642.
33. Johnson D, Lardy H. Isolation of liver or kidney mitochondria. Meth Enzymol 1967;10:94.
34. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem 1951;193:265-275.
35. Marklund S, Marklund G. Involvement of the superoxide anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 1974;47:469-474.
36. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967;70(1):158-169.
37. Sinha AK. Colorimetric assay of catalase. Analyt Biochem 1972;47:389-394.
38. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Analyt Biochem 1979;95:351-358.
39. Moron MS, Depierre JW, Mannervik B. Levels of glutathione, glutathione reductase and glutathione S-transferase activities in rat lung and liver. Biochim Biophys Acta 1979;582(1):67-78.
40. Al-Hendy A, Lee EJ, Wang HQ, Copland JA. Gene therapy of uterine leiomyomas: adenovirus-mediated expression of dominant negative estrogen receptor inhibits tumor growth in nude mice. Am J Obstet Gynecol 2004;191:1621-1631.
41. Dizdaroglu M, Jaruga P, Birincioglu M, Rodriguez H. Free radical-induced damage to DNA: mechanisms and measurement. Free Radic Biol Med 2002;32(11):1102-1115.
42. Amin A, Hamza AA. Oxidative stress mediates drug-induced hepatotoxicity in rats: a possible role of DNA fragmentation. Toxicology 2005;208:367-375.
43. Engelhardt G, Homma D, Schlegel K, Utzmann R, Schnitzler C. Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 1995;44:423-433.
44. Arafa HMM, Abdel-Wahab MH, El-Shafeey MF, Badary OA, Hamada F. Anti-fibrotic effect of meloxicam in a murine lung fibrosis model. Eur J Pharmacol 2007;564:181-189.
45. Gurocak S, Ure I, Cumaoglu A, Gonul II, Sen I, Tan O, Aricioglu A, Bozkirli I. Renal tissue damage after experimental pyelonephritis: role of anti-oxidants and selective cyclooxygenase-2 inhibitors. J Ped Urol 2009;5:S29-S29.
46. Cimen BM, Cimen BÖ, Eskandari G, Sahin G, Erdogan C, Atik U. In vivo effects of meloxicam, celecoxib, and ibuprofen on free radical metabolism in human erythrocytes. Drug Chem Toxicol 2003;26:169-176.
47. Kim SM, Park KC, Kim HG, Han SJ. Effect of selective cyclooxygenase 2 inhibitor meloxicam on liver fibrosis in rats with ligated common bile ducts. Hepatol Res 2008;38:800-809.
48. Kadiiska M, Gladen B, Baird D, Germolec D, Graham LB, Parker CE, Nyska A, Wachsman JT, Ames BN, Basu S, Brot N, Fitzgerald GA, Floyd RA, George M, Heinecke JW, Hatch GE, Hensley K, Lawson JA, Marnett LJ, Morrow JD, Murray DM, Plastaras J, Roberts LJ 2nd, Rokach J, Shigenaga MK, Sohal RS, Sun J, Tice RR, Van Thiel DH, Wellner D, Walter PB, Tomer KB, Mason RP, Barrett JC. Biomarkers of oxidative stress study II: are oxidation products of lipids, proteins, and DNA markers of CCl4 poisoning? Free Radic Biol Med 2005;38:698-710.
49. Honma S, Takahashi N, Shinohara M, Nakamura K, Mitazaki S, Abe S, Yoshida M. Amelioration of cisplatin-induced mouse renal lesions by acyclooxygenase (COX)-2 selective inhibitor. Eur J Pharmacol 2013;715:181-188.
50. Rios A, Vargas-Robles H, Gámez-Méndez AM, Escalante B. Cyclooxygenase-2 and kidney failure. Prostaglandins Other Lipid Mediat 2012;98(3-4):86-90.
51. Federico A, Morgillo F, Tuccillo C, Ciardiello F, Loguercio C. Chronic inflammation and oxidative stress in human carcinogenesis. Int J Cancer 2007;121:2381-2386.
52. Lu Y, Wahl LM. Oxidative stress augments the production of matrix metalloproteinase-1, cyclooxygenase-2, and prostaglandin E2 through enhancement of NF- B activity in lipopolysaccharide-activated human primary monocytes. J Immunol 2005;175:5423.
53. Nukatsuka M, Fujioka A, Saito H, Uchida J, Takeda S, Unemi N. Prolongation of survival and antitumor activity of antitumor drugs in murine cancer cachexia model. Gan To Kagaku Ryoho 1996;23(7):887-892.
54. Akira S, Kishimoto T. Role of interleukin-6 in macrophage function. Curr Opin Hematol 1996;3:87-93.
55. Shima Y, Iwano M, Yoshizaki K, Tanaka T, Kawase I, Nishimoto N. All-trans-retinoic acid inhibits the development of mesangial proliferative glomerulonephritis in interleukin-6 transgenic mice. Nephron Exp Nephrol 2005;100:e54-e62.
56. Suematsu S, Matsuda T, Aozasa K, Akira S, Nakano N, Ohno S, Miyazaki J, Yamamura K, Hirano T, Kishimoto T. Igg1 plasmacytosis in interleukin 6 transgenic mice. Proc Natl Acad Sci USA 1989;86:7547-7551.
57. Tomiyama-Hanayama M, Rakugi H, Kohara M, Mima T, Adachi Y, Ohishi M, Katsuya T, Hoshida Y, Aozasa K, Ogihara T, Nishimoto N. Effect of interleukin-6 receptor blockage on renal injury in apolipoprotein E-deficient mice. Am J Physiol Renal Physiol 2009;297(3):F679-F684.
58. Hsu CC, Hsu CL, Tsai SE, Fu TYC, Yen GC. Protective effect of Millettia reticulata Benth against ccl4-induced hepatic damage and inflammatory action in rats. J Med Food 2009;12:821-828.
59. Bagalkot V, Lee IH, Yu MK, Lee E, Park S, Lee JH, Jon S. A combined chemoimmuno therapy approach using a plasmid-doxorubicin complex. Mol Pharm 2009;6(3):1019-1028.
60. Lin MC, Yin MC. Preventive effects of ellagic acid against doxorubicin-induced cardio-toxicity in mice. Cardiovasc Toxicol 2013;13(3):185-193.
61. Sauter KA, Wood LJ, Wong J, Iordanov M, Magun BE. Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome. Cancer Biol Ther 2011;11(12):1008-1016.
62. Zhu J, Zhang J, Xiang D, Zhang Z, Zhang L, Wu M, Zhu S, Zhang R, Han W. Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity. Eur J Pharmacol 2010;643:247-253.
63. Ding WX, Ong NC. Role of oxidative stress and mitochondrial changes in cyanobacteria induced apoptosis and hepatotoxicity. FEMS Microbiol Lett 2003;220:1-7.
64. 2+ homeostasis. Neurosci Res 2000;37:227-236.
65. Shi J, Aisaki K, Ikawa Y, Wake K. Evidence of hepatocyte apoptosis in rat liver after the administration of carbon tetrachloride. Am J Pathol 1998;153:515.
66. Bajt ML, Vonderfecht SL, Jaeschke H. Differential protection with inhibitors of caspase-8 and caspase-3 in murine models of tumor necrosis factor and Fas receptor-mediated hepatocellular apoptosis. Toxicol Appl Pharmacol 2001;175:243-252.
67. Guicciardi M, Gores G. Apoptosis: a mechanism of acute and chronic liver injury. Gut 2005;54:1024.
68. Sanchez PL, Salgado LM, Ferreri NR, Escalante B. Effect of cyclooxygenase-2 inhibition on renal function after renal ablation. Hypertension 1999;34:848-853.
69. Wang JL, Cheng HF, Shappell S, Harris RC. A selective cyclooxygenase-2 inhibitor decreases proteinuria and retards progressive renal injury in rats. Kidney Int 2000;57:2334-2342.
70. Komers R, Lindsley JN, Oyama TT, Anderson S. Cyclo-oxygenase-2 inhibition attenuates the progression of nephropathy in uninephrectomized diabetic rats. Clin Exp Pharmacol Physiol 2007;34:36-41.
71. Komers R, Lindsley JN, Oyama TT, Schutzer WE, Reed JF, Mader SL, Anderson S. Immunohistochemical and functional correlations of renal cyclooxygenase-2 in experimental diabetes. J Clin Invest 2001;107(7):889-898.
72. Cheng HF, Wang CJ, Moeckel GW, Zhang MZ, mckanna JA, Harris RC. Cyclooxygenase-2 inhibitor blocks expression of mediators of renal injury in a model of diabetes and hypertension. Kidney Int 2002;62(3):929-939.